Drug
Gia632
Gia632: highest development phase Phase 2, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| GIA632 NCT07775924 | Phase 2 | Cutaneous Lichen Planus |
| GIA632 NCT07431177 | Phase 2 | Non-segmental Vitiligo |
Latest
No recent events.
Follow Gia632 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.